[PDF] from umm.ac.idM Pimentel, A Lembo, WD Chey… - … England Journal of …, 2011 - Mass Medical Soc In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an ... Cited by 53 - Related articles - All 10 versions
R Krause, I Zollner-Schwetz, T Valentin… - … England Journal of …, 2011 - Mass Medical Soc Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)1 on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the development of resistance was not investigated in TARGET 1 or TARGET 2 (ClinicalTrials.gov numbers, ... Related articles - All 2 versions
M Piché, M Bouin, M Arsenault, P Poitras… - Neuroscience, 2011 - Elsevier Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder involving abdominal pain and bowel dysfunction. IBS pain symptoms have been hypothesized to depend on peripheral and central mechanisms but the patho-physiology is still unclear. The aim of the present ...
[HTML] from nih.govT Rinttilä, A Lyra, L Krogius-Kurikka… - Gut Pathogens, 2011 - ncbi.nlm.nih.gov Growing amount of scientific evidence suggests that microbes are involved in the pathophysiology of irritable bowel syndrome (IBS). The predominant fecal microbiota composition of IBS subjects has been widely studied with DNA-based techniques but less research has been focused ... Related articles - All 3 versions
[PDF] from hindawi.comHA Hutchings, K Wareham, JN Baxter, P Atherton… - 2011 - downloads.hindawi.com International Scholarly Research Network ISRN Gastroenterology Volume 2011, Article ID 206103, 8 pages doi:10.5402/2011/206103 ... Study of Aloe vera in Patients with Irritable Bowel Syndrome: ... HA Hutchings,1 K. Wareham,2 JN Baxter,3 P. Atherton,4 JGC Kingham,5 P. ... Related articles - View as HTML - All 2 versions